Biotechnology Companies with Great Potential - Seite 2

Gilead Sciences, Inc. (NASDAQ: GILD)

Market Cap: 107.22B, current share price: $81.83 

GILD announced this week that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018. He will remain with the company through July. John McHutchison, MD, currently Executive Vice President, Clinical Research, will be appointed Chief Scientific Officer and assume responsibility for the company's research and development organization. Also effective in April, Andrew Cheng, MD, PhD, Executive Vice President, Clinical Research & Development Operations, will be appointed Chief Medical Officer. Both Dr. McHutchison and Dr. Cheng will report to John Milligan, PhD, Gilead's President and Chief Executive Officer.

Amgen, Inc. (NASDAQ: AMGN)

Market Cap: 136.87B, current share price: $190.01 

AMGN recently announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of Monday, March 5, 2018.

Amgen has accepted for purchase 52,083,333 shares of its common stock, $0.0001 par value per share, at a price of $192 per share, for an aggregate cost of approximately $10 billion, excluding fees and expenses relating to the tender offer. These shares represent approximately 7.2 percent of the shares outstanding. The tender offer was oversubscribed and pursuant to the terms of the tender offer, shares will be accepted on a pro rata basis. Amgen has been informed by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, that the proration factor for the tender offer is approximately 96.2 percent.

Biogen, Inc. (NASDAQ: BIIB)

Market Cap: 59.82B, current share price: $282.77 

BIIB announced this week an agreement to acquire from Pfizer Inc. PF-04958242, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages.